Cellectis S.A. - ADR (CLLS)
Market Closed
27 Jul, 20:00
$
2. 89
+0.05
+1.7606%
$
281.17M Market Cap
- P/E Ratio
- Div Yield
3,464 Volume
-1.27 Eps
$ 2.84
Previous Close 
Want to track CLLS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032. Data update from phase 1/2 NATHALI-01 study, using UCART20x22 for the treatment of patients with B-cell non-Hodgkin lymphoma, expected by the end of 2024.
Seekingalpha | 2 years ago
